These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28986510)

  • 1. Combined
    Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Giskeødegård GF; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
    J Nucl Med; 2018 May; 59(5):762-768. PubMed ID: 28986510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PET/MRI study towards finding the optimal [
    Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of fluciclovine (
    Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
    Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of
    Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
    AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
    Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of
    Jambor I; Kuisma A; Kähkönen E; Kemppainen J; Merisaari H; Eskola O; Teuho J; Perez IM; Pesola M; Aronen HJ; Boström PJ; Taimen P; Minn H
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):355-364. PubMed ID: 29147764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Including Bone in Dixon-Based Attenuation Correction for
    Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
    J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
    Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
    Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Albano D; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Ann Nucl Med; 2020 Feb; 34(2):81-86. PubMed ID: 31773466
    [No Abstract]   [Full Text] [Related]  

  • 13. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biexponential apparent diffusion coefficients values in the prostate: comparison among normal tissue, prostate cancer, benign prostatic hyperplasia and prostatitis.
    Liu X; Peng W; Zhou L; Wang H
    Korean J Radiol; 2013; 14(2):222-32. PubMed ID: 23483254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
    Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of
    Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
    AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
    [No Abstract]   [Full Text] [Related]  

  • 19. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of prostate cancer aggressiveness using
    Movahedi P; Merisaari H; Perez IM; Taimen P; Kemppainen J; Kuisma A; Eskola O; Teuho J; Saunavaara J; Pesola M; Kähkönen E; Ettala O; Liimatainen T; Pahikkala T; Boström P; Aronen H; Minn H; Jambor I
    Sci Rep; 2020 Jun; 10(1):9407. PubMed ID: 32523075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.